Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors ...

Biogen (NASDAQ:BIIB – Get Free Report) had its target price reduced by analysts at JPMorgan Chase & Co. from $220.00 to ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

We recently compiled a list of the 10 Best QQQ Stocks to Buy According to Analysts. In this article, we are going to take a ...

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB.

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority ...